Pfizer Ltd.
NSE: PFIZERPfizer Ltd.: A 30-second snapshot
Pfizer India (NSE: PFIZER) trades at Rs 4,954.7, up 20.0% over 12 months but marginally below its 200-DMA of Rs 5,000 and 15.6% below the 52-week high. The company reported a Q4 profit slide alongside a Rs 75/share special dividend, illustrating the tension between capital returns and a 5-year earnings CAGR of -39.6%.
P/E
30.7
Forward P/E
26.1
ROE
+17.2%
Debt / Equity
1.67
Profit Margin
+28.7%
Div. Yield
+1.5%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
60/100
News
8 headlines · 4 positive · 1 negative
Pfizer Declares Bumper Dividend Of Rs 75/Share Even As Q4 Profit Slides; Check Record Date - NDTV Profit
NDTV Profit
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance - Business Wire
Business Wire
Pfizer Tops Sales Estimates as Older Blockbusters Outperform - Bloomberg.com
Bloomberg.com
Pfizer secures deals to keep heart drug free of generic rivals until 2031 - Reuters
Reuters
Pfizer Receives ₹85.74 Crore Income Tax Assessment Order and Penalty Notice - scanx.trade
scanx.trade
Recent context
- ·Pfizer India declared a special dividend of Rs 75/share alongside Q4 FY26 results, even as Q4 profit declined; the dividend decision reflects the cash-generative nature of the business but contrasts with the earnings trend.
- ·Q1 2026 results showed older blockbusters outperforming estimates with guidance reaffirmed; separately, Reuters reported a patent settlement securing the heart-drug from generic competition until 2031.
- ·An income-tax assessment order of Rs 85.74 crore with an associated penalty notice was disclosed in April 2026, representing a contingent liability to be addressed in upcoming filings.
Strengths
- +ROE of 17.2% ranks 1st among the 6 pharma peers with available data (Cipla 11.7%, Dr. Reddy's 11.8%), and has exceeded 15% in 4 of the available years.
- +Profit margin of 28.7% is well above the generic-pharma peer group, reflecting the branded and specialty mix of the India franchise.
- +Debt trend is falling and D/E of 1.67 is declining, while free cash flow has been positive in 4 of the available years, yielding a fundamental consistency score of 56.
- +A patent settlement securing the heart-drug franchise from generic competition until 2031 provides near-term revenue visibility for that product line.
Weaknesses
- −5-year earnings CAGR of -39.6% signals sustained profit contraction over the medium term, even as revenue grew at 6.3% CAGR, indicating cost or pricing pressures have materially eroded the bottom line.
- −Price has effectively stalled over the past 3 months (-0.12%) and sits below the 200-DMA, with a 52-week drawdown of -15.6% from the peak; the annual gain appears concentrated in an earlier period.
- −Quality score of 46 out of 100 ranks 3rd of 6 peers, and the fundamental consistency score of 56 reflects only 4 of available years with ROE above 15% and FCF positive.
- −A Rs 85.74 crore income-tax assessment order and penalty notice was disclosed in April 2026, adding regulatory-financial uncertainty to the near-term picture.
Open questions
- ?Does the 5-year earnings contraction of -39.6% reflect a structural shift in the India pharma pricing environment, or is it specific to Pfizer India's product-mix transition between patent-protected and off-patent molecules?
- ?How has free cash flow conversion held up relative to reported net profit during the period of earnings decline, and what does that imply for the quality of the remaining earnings base?
- ?Does the 2031 patent protection on the heart-drug franchise represent a meaningful share of total India revenue, and what happens to the revenue profile as that exclusivity period approaches its end?
- ?How does the Rs 85.74 crore tax assessment order compare in magnitude to prior tax disputes in Pfizer India's history, and what has been the typical resolution timeline and outcome?
Peer comparison: Pharma
Ranks 3 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| PFIZER | Pfizer Ltd.You're viewing | 30.7 | +17.2% | 46 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.7 | +11.8% | 17 |
Technical state
Current price
₹4,954.70
SMA 50
₹4,785.21
SMA 200
₹5,000.17
RSI (14)
58.1 (neutral)
From 52w high
-15.6%
1Y return
+20.0%
3M return
-0.1%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- medium5-year earnings CAGR is -39.6% — earnings have contracted sharply over the period even as revenue grew at 6.3% CAGR, pointing to sustained margin and cost pressure rather than a one-off event.
- mediumStock at 4,954.7 trades below its 200-DMA of 5,000.17 (gap of ~0.9%) and is 15.6% below the 52-week high, with near-zero 3-month price change (-0.12%), indicating price stagnation around the long-term trend.
- mediumDebt-to-equity of 1.67 is above the pharma-sector norm for a predominantly domestic franchise; debt trend is falling, but leverage warrants monitoring given continued earnings pressure.
- lowROE data is unavailable for 3 of 5 listed peers (APOLLOHOSP, MAXHEALTH, SUNPHARMA), and 1-year price change data is missing across all 5 peers, making a comprehensive relative return and quality comparison incomplete.
- lowAnalyst coverage is thin at 3 analysts with a mean rating of 1 on the 1-5 scale (lower = more constructive); the small sample limits confidence in consensus reliability.
Cross-section contradictions
- Trailing 1-year price gain of +20.0% coexists with the stock trading below its 200-DMA, suggesting the annual return was front-loaded while recent months have seen the price consolidate near the long-term moving average.
- News sentiment is net-positive (Q1 results beat, bumper dividend of Rs 75/share declared, patent protection secured through 2031) while 5-year earnings CAGR stands at -39.6%, reflecting a divergence between near-term operational headlines and the medium-term earnings trajectory.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days